JP4191797B2 - 組み換えｃ型肝炎ウイルスｒｎａレプリカーゼ - Google Patents

組み換えｃ型肝炎ウイルスｒｎａレプリカーゼ Download PDF

Info

Publication number
JP4191797B2
JP4191797B2 JP51370797A JP51370797A JP4191797B2 JP 4191797 B2 JP4191797 B2 JP 4191797B2 JP 51370797 A JP51370797 A JP 51370797A JP 51370797 A JP51370797 A JP 51370797A JP 4191797 B2 JP4191797 B2 JP 4191797B2
Authority
JP
Japan
Prior art keywords
rdrp
hcv
recombinant hcv
rna
reporter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP51370797A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11514862A (ja
JPH11514862A5 (https=
Inventor
エイチ． ハーゲドーン、カート
エイチ． アル、レイノルダス
Original Assignee
エモリー ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー ユニバーシティー filed Critical エモリー ユニバーシティー
Publication of JPH11514862A publication Critical patent/JPH11514862A/ja
Publication of JPH11514862A5 publication Critical patent/JPH11514862A5/ja
Application granted granted Critical
Publication of JP4191797B2 publication Critical patent/JP4191797B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP51370797A 1995-09-27 1996-09-27 組み換えｃ型肝炎ウイルスｒｎａレプリカーゼ Expired - Fee Related JP4191797B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27
US60/004,383 1995-09-27
PCT/US1996/015571 WO1997012033A1 (en) 1995-09-27 1996-09-27 Recombinant hepatitis c virus rna replicase

Publications (3)

Publication Number Publication Date
JPH11514862A JPH11514862A (ja) 1999-12-21
JPH11514862A5 JPH11514862A5 (https=) 2004-09-30
JP4191797B2 true JP4191797B2 (ja) 2008-12-03

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51370797A Expired - Fee Related JP4191797B2 (ja) 1995-09-27 1996-09-27 組み換えｃ型肝炎ウイルスｒｎａレプリカーゼ

Country Status (8)

Country Link
US (2) US5981247A (https=)
EP (1) EP0859833B1 (https=)
JP (1) JP4191797B2 (https=)
AT (1) ATE318896T1 (https=)
AU (1) AU719122B2 (https=)
CA (1) CA2233309A1 (https=)
DE (1) DE69635864T2 (https=)
WO (1) WO1997012033A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) * 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
JP2002510509A (ja) * 1998-04-02 2002-04-09 バイロファーマ・インコーポレイテッド Ｃ型肝炎ウイルスｎｓ５ｂ組成物およびその使用方法
US6639053B1 (en) 1998-06-24 2003-10-28 Tetsuya Toyoda HCV-derived RNA polymerase gene
WO2000033635A2 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
WO2001077371A1 (fr) * 2000-04-07 2001-10-18 Shionogi & Co., Ltd. Procede de dosage de preincubation
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
US6699657B2 (en) * 2001-01-31 2004-03-02 Bristol-Myers Squibb Company In vitro system for replication of RNA-dependent RNA polymerase (RDRP) viruses
WO2002095002A2 (en) * 2001-05-22 2002-11-28 University Of Chicago N4 virion single-stranded dna dependent rna polymerase
AU2002325755A1 (en) * 2001-09-18 2003-04-01 Affinium Pharmaceuticals, Inc. Methods and apparatuses for purification
US20030104445A1 (en) * 2001-09-25 2003-06-05 Hayes Robert J. RNA dependent RNA polymerase mediated protein evolution
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Ｈｃｖ 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
AU2002360394A1 (en) * 2001-11-16 2003-06-10 University Of Massachusetts Facilitation of rna interference
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
EP1711516A4 (en) * 2004-01-09 2009-12-30 Merck & Co Inc HCV RNA-dependent RNA polymerase
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
AR058419A1 (es) 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales
US7405204B2 (en) 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
TW201004632A (en) 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
EP2166016A1 (en) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
CA2780044A1 (en) 2009-11-14 2011-05-19 F. Hoffmann-La Roche Ag Biomarkers for predicting rapid response to hcv treatment
WO2011067195A1 (en) 2009-12-02 2011-06-09 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to hcv treatment
UY33310A (es) 2010-03-31 2011-10-31 Pharmasset Inc Sintesis estereoselectiva de activos que contienen fosforo
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
MA34462B1 (fr) 2010-07-22 2013-08-01 Novartis Ag Composes de thiophene 2,3,5- trisubstitues et leurs utilisations
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
ATE318896T1 (de) 2006-03-15
JPH11514862A (ja) 1999-12-21
EP0859833A4 (en) 2001-03-28
AU719122B2 (en) 2000-05-04
DE69635864T2 (de) 2006-10-26
US5981247A (en) 1999-11-09
EP0859833A1 (en) 1998-08-26
CA2233309A1 (en) 1997-04-03
AU7200796A (en) 1997-04-17
US6248589B1 (en) 2001-06-19
WO1997012033A1 (en) 1997-04-03
EP0859833B1 (en) 2006-03-01
DE69635864D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
JP4191797B2 (ja) 組み換えｃ型肝炎ウイルスｒｎａレプリカーゼ
WO1997012033A9 (en) Recombinant hepatitis c virus rna replicase
US7148006B2 (en) Screening methods to identify agents that selectively inhibit hepatitis C virus replication
JP3280384B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）のｎｓ３プロテアーゼの蛋白分解活性のインビトロにおける再生方法
Ishii et al. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding
Qin et al. Mutational analysis of the structure and functions of hepatitis C virus RNA–dependent RNA polymerase
Dimitrova et al. Protein-protein interactions between hepatitis C virus nonstructural proteins
JP2007300933A (ja) ヘリカーゼ活性および改善された溶解性を有するｈｃｖｎｓ３タンパク質フラグメント
JPH07101986A (ja) Ｃ型肝炎ウイルスのポリペプチドおよびイムノアッセイ
JP2002511763A (ja) フラビビリデ科のウイルス由来のＡＴＰａｓｅタンパク質を用いるスクリーニング法
EP0763114A2 (en) Hepatitis g virus and molecular cloning thereof
US6461845B1 (en) Recombinant hepatitis C virus RNA replicase
Shoji et al. Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli
JP3878132B2 (ja) 精製活性型ｈｃｖｎｓ２／３プロテアーゼ
JPH05142231A (ja) Ｃ型肝炎診断薬
EP1342084B1 (en) Assay for anti-viral agent
AU684177C (en) Hepatitis G virus and molecular cloning thereof
Daughenbaugh The role of VPg in translation of calicivirus RNA
JPWO1999043792A1 (ja) ヒトｃ型肝炎ウイルスのｒｎａ依存性ポリメラーゼ活性を有する組換え型タンパク及びその製造方法
HK1031899A (en) Novel screening methods to identify agents that selectively inhibit hepatitus c virus replication
Patel An Investigation of the Complexes Formed Between the Hepatitis C Virus E1 and E2 Glycoproteins
CZ314999A3 (cs) Způsoby pro vyhledávání nových antivirových činidel

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080902

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080919

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110926

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110926

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120926

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130926

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees